IGC Pharma, Inc. IGC
0.19 USD -0.01 (-3.58%)
At closeNov 3, 2026, 4:00 PM EST
0.19 +0.01 +3.23%
After hours · Nov 3, 4:00 PM ET
0.185 Day range 0.20
0.08 52-week range 0.40
- YTD
- -33.57%
- 1 year
- -53.50%
- Market cap
- 19.23M
- Revenue (ttm)
- 1.06M
- EPS (ttm)
- -0.07
- Shares out
- 77.45M
- Forward P/E
- -3.74
- YTD return
- -33.57%
- 1-year return
- -53.50%
- Volume
- 350.50K
- Avg volume
- 752.91K
- Open
- 0.1927
- Previous close
- 0.1929
- Day's range
- 0.185 – 0.20
- 52-week range
- 0.08 – 0.40
- Beta
- 1.29
- Price target
- 3.75 (+1916.1%)
- Earnings date
- Feb 12, 2025
5D -0.0530 (-21.20%)
Key statistics
- Enterprise value
- 26.29M
- PEG ratio
- 0.00
- Price / sales
- 27.25
- Price / book
- 3.40
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -51.00%
- Free cash flow
- -3.51M
- Total cash
- 1.82M
- Total debt
- 338.00K
- Return on equity
- -126.20%
- Short % of float
- 2.40%
- 50-day average
- 0.3768
- 200-day average
- 0.421
Analyst view
Price target (mean) 3.75 +1916.1% upside
Now 0.186
- Target (low)
- 3.50
- Target (mean)
- 3.75
- Target (high)
- 4.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 12, 2025
Expected Feb 12, 2025. Consensus EPS estimate -0.03.
Financials — quick view
IGC Revenue — quarterly 265.00K
IGC Net income — quarterly -2.94M
IGC EPS — quarterly -0.03
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 12, 2025 | Dec 1, 2024 | -0.03 | — | — | — |
| Nov 12, 2024 | Sep 1, 2024 | -0.03 | -0.02 | +0.01 | +33.33% |
| Aug 8, 2024 | Jun 1, 2024 | 0.00 | -0.03 | — | — |
| Jun 24, 2024 | Mar 1, 2024 | 0.00 | -0.04 | — | — |
| Feb 14, 2024 | Dec 1, 2023 | 0.00 | -0.09 | — | — |
| Nov 9, 2023 | Sep 1, 2023 | 0.00 | -0.05 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 5, 2024 | Ascendiant Capital | main | Buy | Buy |
| Sep 3, 2024 | Ascendiant Capital | main | Buy | Buy |
| Jul 29, 2024 | Ascendiant Capital | main | Buy | Buy |
| Jul 17, 2024 | Alliance Global Partners | init | — | Buy |
| Jun 21, 2024 | Ascendiant Capital | reit | Buy | Buy |
About IGC Pharma, Inc.
IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- igcpharma.com
News
Why Celestica Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket 
12 Health Care Stocks Moving In Wednesday's After-Market Session 
IGC Pharma Unveils PRISM AI Platform to Move Alzheimer's Risk Prediction to Brain-Health Action and Commercial Deployment 
IGC Pharma, Inc. (NYSEAMERICAN:IGC) Stock Short Interest Jumps 48.0% 
'DEA Judge Pauses Marijuana Rescheduling Hearing As Opponents Highlight Government Report Detailing ‘Gaps’ In Federal Processes'- Marijuana Moment 
IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026 
Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $6 
IGC Pharma Q2 EPS $(0.03) Misses $(0.02) Estimate, Sales $265.000K Beat $258.000K Estimate 
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure 
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout
Your note
Sign in to keep a note on IGC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRADBURY STRATEGIC INVESTMENT FUND A | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Mar 21, 2024 | 13,823,500 |
| GRIMALDI CLAUDIA | Director | Conversion of Exercise of derivative security | Mar 12, 2024 | 1,037,150 |
| MORAN JAMES P | Director | Purchase | Sep 24, 2024 | 0 |
| MUKUNDA RAM | Chief Executive Officer | Stock Gift | Mar 12, 2024 | 4,336,760 |
| PRINS RICHARD K | Director | Stock Gift | Aug 11, 2024 | 1,042,920 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 1.78% | 703,798 | 263.01K | Sep 29, 2024 |
| Vanguard Group Inc | 1.63% | 645,166 | 241.10K | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.42% | 562,969 | 210.38K | Sep 29, 2024 |
| State Street Corporation | 0.42% | 165,307 | 61.77K | Sep 29, 2024 |
| Virtu Financial LLC | 0.31% | 123,060 | 45.99K | Sep 29, 2024 |
| Dearborn Partners, L.L.C. | 0.29% | 116,401 | 43.50K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 1.59% | 630,222 | 235.51K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.98% | 387,255 | 144.72K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.25% | 99,144 | 37.05K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.23% | 91,469 | 34.18K | Oct 30, 2024 |